I cannot provide a meaningful answer to your question "Volume 7A, Chapter 57" because you have not asked a specific question about the content.
The passages provided reference FMR Volume 7A, Chapter 57 (Reserve Entitlements for Active Duty) and related chapters covering topics such as:
- Reserve member BAH and BAS entitlements [DAFMAN 65-116V3 para 10.4.1]
- Incapacitation Pay for members with service-connected injuries [DAFI 36-2910 para 7.2.1]
- Involuntary active duty service requirements [DoDI 7770.02]
- Reserve component pay and allotments [FMR Volume 7A, Chapter 58 para 2.5.1]
Please ask a specific question about reserve entitlements, pay, allowances, or related topics, and I will answer using only these indexed passages.
Unofficial — answered from indexed publication text, which may be incomplete or out of date. Your MAJCOM/unit supplement may be stricter. Verify the official PDF before acting or writing a finding.
DAFMAN 65-116V3 para 10.4.1, p. 84 (effective/current as of 2026-02-19)Member should provide the contact information for the spouse’s organization to determine spouse’s status. When the member’s spouse is in an active duty status the BAH entitlement for both members should be reviewed to ensure the allowance is paid correctly. When the spouse is not in an active duty status during the IADT period, the member attending IADT is entitled to with dependent rate BAH. 10.3.2. BAS. See DOD 7000.14-R Volume 7A, Chapters 25 and 57. Note: NPS members are not entitled to BAS during BMT. They may be entitled while attending Technical Training. 10.3.3. Family Separation Allowance. See DOD 7000.14-R Volume 7A, Chapters 27 and 57 10.4. Reserve Pay Office Actions (Out-processing). 10.4.1. Ensure member was completely gained in DJMS-RC prior to accomplishing out- processing a
DAFI 36-2910 para 7.2.1, p. 169 (effective/current as of 2025-11-19)Specialty Code, as determined by a military medical authority and the member’s immediate commander, due to an injury, illness or disease incurred or aggravated ILOD, is eligible for full pay and allowances (including incentives and special pays to which entitled, if otherwise eligible) in accordance with paragraph 7.2, and less any civilian earned income the member has, regardless of type of duty status. (T-0). If there is no civilian income, there is no offset of monies and member is entitled to full INCAP Pay. (T-0). Reference DoD 7 Financial Management Regulation (FMR) 7000.14-R, Military Pay Policy –Active Duty and Reserve Pay, Volume 7A, Chapter 57, Table 57-3. Note: Voluntary leave of absence or voluntary termination of employment from civilian employment does not constitute a loss o
No supplement passage retrieved — check the supplement chain on the pub page before citing.
DoDI 7770.02 (effective/current as of 2025-12-04)ment: A Completed 547 continuous days of AD under involuntary orders. B Completed 730 cumulative days of involuntary AD during the previous 1,826 days. C On involuntary orders for 180 days or more within the 180 days following separation from a previous involuntary AD period of 180 days or more. D Continuation or establishment of eligibility due to AD in accordance with Section 12301(h) of Title 10, U.S.C. Reference Chapter 55 of Volume 7A of DoD 7000.14- R 1 Character Y Y N N 143 Incapacitation Pay Paid Current Month Amount The total amount paid this month to compensate for the difference between their civilian pay and what their AD pay and entitlements would be while incapacitated. Reference Chapter 57 of Volume 7A of the DoD 7000.14-R. Formatted in accordance with Paragraph 3.2.b.(5). 9
40 CFR 261.33 para 261.33 (effective/current as of 2026-07-15)yrazinyl phosphorothioate P043 55-91-4 Diisopropylfluorophosphate (DFP) P004 309-00-2 1,4,5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexa- chloro-1,4,4a,5,8,8a,-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- P060 465-73-6 1,4,5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexa- chloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5beta,8beta,8abeta)- P037 60-57-1 2,7:3,6-Dimethanonaphth[2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta,6aalpha,7beta, 7aalpha)- P051 1 72-20-8 2,7:3,6-Dimethanonaphth [2,3-b]oxirene, 3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2abeta,3alpha,6alpha,6abeta,7beta, 7aalpha)-, & metabolites P044 60-51-5 Dimethoate P046 122-09-8 alpha,alpha-Dimethylphenethylamine P191 644-64-4 Dimeti
Official source: https://www.ecfr.gov/current/title-40/section-261.33